Skip to Main content Skip to Navigation
Journal articles

The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer

Abstract : Purpose: To analyze the clinical outcomes and the safety of preoperative high-dose-rate (HDR) image-guided adaptive brachytherapy (IGABT) followed by minimally invasive surgery (MIS) in the multidisciplinary management of early-stage cervical cancer. Methods and materials: Medical records of all consecutive patients with early-stage cervical cancer treated at our institution between 2012 and 2018 with preoperative IGABT in a multidisciplinary approach were reviewed. Treatment schedule was pelvic node dissection, preoperative IGABT followed 6-8 week later by MIS hysterectomy. Results: Seventy patients with cervical cancer FIGO stages (IB1 18.6%, IB2 75.7% and IIA1 5.7%) were treated by preoperative HDR brachytherapy. With a median follow-up of 37.4 months [95% confidence interval, 32.1-39.7 months] isolated vaginal vault recurrence was not observed, 3 pelvic relapses were reported (4.3%). None of patients received postoperative radiotherapy (EBRT) or radiochemotherapy. The estimated 3-year local and pelvis relapse free survival for the entire population were respectively 98% [95% confidence interval, 89%-100%] and 90% [80%-96%]. The estimated 3-year disease-free survival (DFS) for the entire population was 88% [77-94%]. The 3-year overall survival (OS) rate was 97% [88%-99%]. Microscopic vaginal resection margin (R1) was observed in one patient ([1].4%). Lymph-vascular space invasion (LVSI) was found found in 6 (8.6%) patients. Forty-eight late complications in 36 patients (51.4%) were observed. Five (7.1%) grade 3 vaginal wound dehiscence toxicities were observed. Urinary and gastrointestinal toxicities were grade 1-2. No grade 4-5 complications were observed. Conclusions: Preoperative image-guided adaptive brachytherapy followed by minimally invasive surgery allows high local control, reduces positive surgical margins and rates of lymph-vascular space invasion avoiding adjuvants treatments. Surgical approaches must be discussed with patients including preoperative brachytherapy as a down-staging treatment.
Document type :
Journal articles
Complete list of metadata
Contributor : Odile Malbec Connect in order to contact the contributor
Submitted on : Friday, April 22, 2022 - 4:30:41 PM
Last modification on : Tuesday, May 31, 2022 - 10:56:18 AM
Long-term archiving on: : Saturday, July 23, 2022 - 7:14:30 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Leonel Varela Cagetti, Laurence Gonzague-Casabianca, Christophe Zemmour, Eric Lambaudie, Gilles Houvenaeghel, et al.. The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer. Gynecologic Oncology, Elsevier, 2021, 161 (1), pp.166 - 172. ⟨10.1016/j.ygyno.2021.01.034⟩. ⟨inserm-03649584⟩



Record views